Expression of SLC39A6 is a strong prognostic indicator in breast cancer, with high levels associated with a good prognosis in luminal subtypes, but predicting poor survival and failure to respond to treatment in triple negative breast cancer (164, 194, 225). This evidence concerns the gene SLC39A6 and triple-negative breast carcinoma.